文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

肺癌、慢阻肺与特发性肺纤维化患者临终医疗与姑息治疗使用差异比较研究

Differences in Health Care and Palliative Care Use at the End of Life: A Comparison Study Among Lung Cancer, COPD, and Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Chest · 2024-08-24
一句话结论与肺癌患者相比,慢阻肺和特发性肺纤维化患者临终前门诊姑息治疗和阿片类处方更少、ICU使用更多。

该回顾性研究纳入加州大学旧金山分校生命最后6个月内至少1次门诊就诊的1819例已故肺癌、慢阻肺或特发性肺纤维化患者,比较最后6个月的门诊姑息治疗、阿片类处方、住院姑息治疗、住院、ICU使用和院内死亡,以肺癌为参照组计算校正OR。慢阻肺和特发性肺纤维化患者门诊姑息治疗(aOR 0.26、0.48)和阿片类处方(aOR 0.50、0.40)均低于肺癌,临终ICU使用更高(aOR 2.88、4.15)。特发性肺纤维化患者住院姑息治疗几率高于肺癌(aOR 2.02)。作者认为需进一步研究医疗系统障碍以优化生活质量和契合患者目标。

要点

  • 与肺癌相比,慢阻肺患者门诊姑息治疗aOR 0.26(95%CI 0.19-0.36)、特发性肺纤维化aOR 0.48(95%CI 0.32-0.70),均P<.001。
  • 与肺癌相比,慢阻肺患者门诊阿片类处方aOR 0.50(95%CI 0.40-0.63)、特发性肺纤维化aOR 0.40(95%CI 0.29-0.54)。
  • 与肺癌相比,慢阻肺患者临终ICU使用aOR 2.88(95%CI 2.11-3.93)、特发性肺纤维化aOR 4.15(95%CI 2.66-6.49),均P<.001。
  • 特发性肺纤维化患者住院姑息治疗几率高于肺癌(aOR 2.02,95%CI 1.30-3.13,P=.002)。
  • 作者认为需进一步研究医疗系统障碍,以优化生活质量和契合患者治疗目标。

适用人群与场景

  • 已故肺癌、慢阻肺或特发性肺纤维化患者,且生命最后6个月内至少1次在加州大学旧金山分校门诊就诊。

研究设计与关键结果

  • 回顾性研究,纳入1819例已故肺癌、慢阻肺或特发性肺纤维化患者,比较生命最后6个月的门诊姑息治疗、阿片类处方、住院姑息治疗、住院、ICU使用和院内死亡,以肺癌为参照组行多因素logistic回归计算aOR。
  • 与肺癌相比,慢阻肺和特发性肺纤维化患者门诊姑息治疗aOR分别为0.26(95%CI 0.19-0.36)和0.48(95%CI 0.32-0.70),P<.001。
  • 与肺癌相比,慢阻肺和特发性肺纤维化患者门诊阿片类处方aOR分别为0.50(95%CI 0.40-0.63)和0.40(95%CI 0.29-0.54)。
  • 与肺癌相比,慢阻肺和特发性肺纤维化患者临终ICU使用aOR分别为2.88(95%CI 2.11-3.93)和4.15(95%CI 2.66-6.49)。
  • 特发性肺纤维化患者住院姑息治疗aOR为2.02(95%CI 1.30-3.13),P=.002。
  • 慢阻肺和特发性肺纤维化患者较肺癌患者更可能为男性且死亡时年龄更大。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with lung cancer, idiopathic pulmonary fibrosis (IPF), and COPD have high symptom burden, poor quality of life, and high health care use at the end of life. Although proactive integration of palliative care in lung cancer can improve outcomes, it is unclear whether similar practices have been adopted in COPD and IPF care.

RESEARCH QUESTION: Do patients with COPD and IPF have different patterns of health care and palliative care use at the end of life compared with patients with lung cancer?

STUDY DESIGN AND METHODS: We retrospectively identified deceased patients with lung cancer, COPD, or IPF with ≥ 1 outpatient visit at the University of California, San Francisco, in the last 6 months of life. We compared outpatient palliative care and opioid prescriptions, inpatient palliative care, hospitalizations, intensive care use, and in-hospital death in the last 6 months of life between each group. We used multivariable logistic regression to calculate adjusted ORs (aORs) of each outcome, with lung cancer as the reference group.

RESULTS: Among 1,819 patients, patients with COPD and IPF were more likely to be male and older at the time of death compared with patients with lung cancer. Compared with patients with lung cancer, patients with COPD and IPF showed a lower adjusted odds (P < .001) of receiving outpatient palliative care (COPD: aOR, 0.26 [95% CI, 0.19-0.36]; IPF: aOR, 0.48 [95% CI, 0.32-0.70]), outpatient opioid prescription (COPD: aOR, 0.50 [95% CI, 0.40-0.63]; IPF: aOR, 0.40 [95% CI, 0.29-0.54]), and a higher odds of end-of-life ICU use (COPD: aOR, 2.88 [95% CI, 2.11-3.93]; IPF: aOR, 4.15 [95% CI, 2.66-6.49]). Patients with IPF showed higher odds of receiving inpatient palliative care (aOR: 2.02 [95% CI, 1.30-3.13]; P = .002).

INTERPRETATION: This study showed that patients with COPD and IPF are less likely to receive outpatient palliative care and opioid prescriptions and are more likely to use end-of-life intensive care than patients with lung cancer. Further research should explore health system barriers contributing to differences in care patterns to optimize quality of life and to align with patient goals of care.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Suen AO, Bischoff K, Iyer AS, et al. Differences in Health Care and Palliative Care Use at the End of Life: A Comparison Study Among Lung Cancer, COPD, and Idiopathic Pulmonary Fibrosis. Chest. 2024. PMID: 39186972. doi:10.1016/j.chest.2024.08.018

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。